A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Summary

The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.

Timeline

Start

2009-05

Primary completion

2012-06

Completion

2013-06

Outcome

Missed primary endpoint

paper Thus, the study did not reach its primary endpoint. PMID 24035405 ↗

Publications

• Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11.

Drugs

Indications